The historical rank and industry rank for ARIAD Pharmaceuticals's Gross Margin % or its related term are showing as below:
ARIA's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.43 * Ranked among companies with meaningful Gross Margin % only.
ARIAD Pharmaceuticals had a gross margin of 97.54% for the quarter that ended in Sep. 2016 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for ARIAD Pharmaceuticals was 0.00% per year.
ARIAD Pharmaceuticals Gross Margin % Historical Data
The historical data trend for ARIAD Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ARIAD Pharmaceuticals's Gross Margin %
For the Biotechnology subindustry, ARIAD Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARIAD Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARIAD Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ARIAD Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ARIAD Pharmaceuticals had a gross margin of 97.54% for the quarter that ended in Sep. 2016 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ARIAD Pharmaceuticals Gross Margin % Related Terms
Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description
ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARIA has been successfully added to your 